Ajay Aggarwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ajay Aggarwal has a total of 468 co-authors. Here are the top co-authors by number of shared publications:
- Richard Sullivan
Institute of Cancer Policy, King’s College London, London, UK
22 shared publications Jan van der Meulen
Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK; Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK
16 shared publications- Jan van der Meulen
Department of Health Services Research and Policy London School of Hygiene and Tropical Medicine London UK
15 shared publications Richard Sullivan
Institute of Cancer Policy, King's College London, London, UK
12 shared publications- Julie Nossiter
Department of Health Services Research and Policy The London School of Hygiene and Tropical Medicine (LSHTM) London UK
9 shared publications - Daniel Lewis
London School of Hygiene and Tropical Medicine, London, United Kingdom
7 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Stereotactic Ablative Radiotherapy Versus Surgical Resection for Early-Stage Non–Small Cell Lung Cancer: An Emulated Target Trial
Purpose: Stereotactic ablative radiotherapy (SABR) is standard of care for inoperable early-stage non–small cell lung cancer (NSCLC), but there is little evidence to support SABR as an alternative to surgical resection. Randomized controlled trials (RCTs) have failed to recruit, and ongoing RCTs apply strict inclusion criteria. To our knowledge, this is the first emulated target trial comparing the effectiveness of SABR versus surgery in individuals with early-stage NSCLC eligible for either treatment. Methods: We used England's National Cancer Registry data to identify individuals diagnosed with T1-2N0M0 NSCLC during 2015-2020, age 18-79 years with Zubrod performance status 0-2, or age 80+ years with performance status 0-1, who underwent SABR or surgical resection within 6 months of diagnosis. Treatment receipt was identified via linkage to Hospital Episode Statistics and the National Radiotherapy Data Set. The primary outcome was 3-year all-cause mortality; secondary outcomes included lung cancer–specific mortality and recurrence. An instrumental variable analysis reduced the risk of confounding by indication. Results: A total of 12,546 met the eligibility criteria (2,299 SABR; 10,247 surgery). After adjustment, 3-year all-cause mortality estimates were 30.3% (SABR) and 21.6% (surgery; mean absolute risk difference 8.8 percentage points [pp], [95% CI, 1.4 to 16.2]; P = .02). Lung cancer–specific mortality estimates were 20.6% (SABR) and 14.5% (surgery; mean absolute risk difference 6.1 pp [95% CI, –0.6 to 12.9]; P = .07). The adjusted mean absolute risk difference in 3-year all-cause mortality for those age 80+ years was 4.3 pp ([95% CI, –3.7 to 12.3]; P = .62). Conclusion: This emulated target trial found higher 3-year all-cause mortality after SABR versus surgery in early-stage NSCLC suitable for either modality, supporting that surgical resection should remain the preferred option. The findings support SABR as a curative-intent alternative, particularly for older people.
- 2 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Open AccessStereotactic Ablative Radiotherapy Versus Surgical Resection for Early-Stage Non–Small Cell Lung Cancer: An Emulated Target Trial
Purpose: Stereotactic ablative radiotherapy (SABR) is standard of care for inoperable early-stage non–small cell lung cancer (NSCLC), but there is little evidence to support SABR as an alternative to surgical resection. Randomized controlled trials (RCTs) have failed to recruit, and ongoing RCTs apply strict inclusion criteria. To our knowledge, this is the first emulated target trial comparing the effectiveness of SABR versus surgery in individuals with early-stage NSCLC eligible for either treatment. Methods: We used England's National Cancer Registry data to identify individuals diagnosed with T1-2N0M0 NSCLC during 2015-2020, age 18-79 years with Zubrod performance status 0-2, or age 80+ years with performance status 0-1, who underwent SABR or surgical resection within 6 months of diagnosis. Treatment receipt was identified via linkage to Hospital Episode Statistics and the National Radiotherapy Data Set. The primary outcome was 3-year all-cause mortality; secondary outcomes included lung cancer–specific mortality and recurrence. An instrumental variable analysis reduced the risk of confounding by indication. Results: A total of 12,546 met the eligibility criteria (2,299 SABR; 10,247 surgery). After adjustment, 3-year all-cause mortality estimates were 30.3% (SABR) and 21.6% (surgery; mean absolute risk difference 8.8 percentage points [pp], [95% CI, 1.4 to 16.2]; P = .02). Lung cancer–specific mortality estimates were 20.6% (SABR) and 14.5% (surgery; mean absolute risk difference 6.1 pp [95% CI, –0.6 to 12.9]; P = .07). The adjusted mean absolute risk difference in 3-year all-cause mortality for those age 80+ years was 4.3 pp ([95% CI, –3.7 to 12.3]; P = .62). Conclusion: This emulated target trial found higher 3-year all-cause mortality after SABR versus surgery in early-stage NSCLC suitable for either modality, supporting that surgical resection should remain the preferred option. The findings support SABR as a curative-intent alternative, particularly for older people.
- Open Access
- 22 October 2026
- Published by Elsevier in SSRN Electronic Journal
Improving Radiotherapy-Induced Gastrointestinal Toxicity Detection: A Prospective Cross-Sectional Survey Study of ALERT-B in Botswana
ObjectivesBotswana has a high incidence of locally advanced cervical cancer which requires radiotherapy for cure. CTCAE toxicity reporting in this setting is difficult. The aim of this study is to utilize a patient-designed gastrointestinal (GI) toxicity survey (ALERT-B) to quantify toxicities after pelvic radiotherapy for cervical cancer in Botswana and validate the study’s use as a patient-centered alternative reporting system in this population.Design/setting/participantsALERT-B GI toxicity questionnaire and a GI-specific CTCAE toxicity questionnaire were administered 07/2024-05/2025 to cervical cancer patients who completed curative radiotherapy in Botswana 6-18 months post-treatment.ResultsMedian age (n=93) was 53 (IQR: 46-59); 67.7% were HIV-positive. FIGO Stages IB-IVB represented; most patients presenting at Stage II (n=36) or Stage III (n=34). Treatment included chemoradiotherapy(CRT) (n=60), radiotherapy(RT) (n=22), surgery+CRT (n=6), chemotherapy+CRT (n=3), and surgery+RT (n=2). In total, 21 and 15 patients reported GI toxicities with Alert-B and CTCAE, respectively. Most reported Alert-B symptom was nocturnal defecation urge (n=12), followed by fecal incontinence (n=8), rectal bleeding (n=7), and impact on daily life (n=4). Most reported CTCAE symptom was diarrhea (n=8), followed by rectal bleeding (n=5), fecal incontinence (n=2), rectal pain (n=1), and pelvic pain (n=1). Patients reported a maximum toxicity level of Grade 2. The Alert-B survey reports an 86.7% (95% CI: 59.5%-98.3%) chance of detecting a toxicity reported on the CTCAE survey. If a toxicity is not reported on the CTCAE survey, there is a 90.2% (95% CI: 81.7%-95.7%) chance ALERT-B agrees. The ALERT-B and CTCAE questionnaires were not statistically different in sensitivity/specificity of reporting toxicity outcomes (p=0.11). ConclusionsGI toxicities in this population are likely underreported. We demonstrated equivalence between the patient-centered ALERT-B and medically-focused CTCAE surveys. In this LMIC setting, ALERT-B offers a path to GI toxicity data collection that improves efficiency and data volume collected, improving patient quality of life.
- 22 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImproving Radiotherapy-Induced Gastrointestinal Toxicity Detection: A Prospective Cross-Sectional Survey Study of ALERT-B in Botswana
ObjectivesBotswana has a high incidence of locally advanced cervical cancer which requires radiotherapy for cure. CTCAE toxicity reporting in this setting is difficult. The aim of this study is to utilize a patient-designed gastrointestinal (GI) toxicity survey (ALERT-B) to quantify toxicities after pelvic radiotherapy for cervical cancer in Botswana and validate the study’s use as a patient-centered alternative reporting system in this population.Design/setting/participantsALERT-B GI toxicity questionnaire and a GI-specific CTCAE toxicity questionnaire were administered 07/2024-05/2025 to cervical cancer patients who completed curative radiotherapy in Botswana 6-18 months post-treatment.ResultsMedian age (n=93) was 53 (IQR: 46-59); 67.7% were HIV-positive. FIGO Stages IB-IVB represented; most patients presenting at Stage II (n=36) or Stage III (n=34). Treatment included chemoradiotherapy(CRT) (n=60), radiotherapy(RT) (n=22), surgery+CRT (n=6), chemotherapy+CRT (n=3), and surgery+RT (n=2). In total, 21 and 15 patients reported GI toxicities with Alert-B and CTCAE, respectively. Most reported Alert-B symptom was nocturnal defecation urge (n=12), followed by fecal incontinence (n=8), rectal bleeding (n=7), and impact on daily life (n=4). Most reported CTCAE symptom was diarrhea (n=8), followed by rectal bleeding (n=5), fecal incontinence (n=2), rectal pain (n=1), and pelvic pain (n=1). Patients reported a maximum toxicity level of Grade 2. The Alert-B survey reports an 86.7% (95% CI: 59.5%-98.3%) chance of detecting a toxicity reported on the CTCAE survey. If a toxicity is not reported on the CTCAE survey, there is a 90.2% (95% CI: 81.7%-95.7%) chance ALERT-B agrees. The ALERT-B and CTCAE questionnaires were not statistically different in sensitivity/specificity of reporting toxicity outcomes (p=0.11). ConclusionsGI toxicities in this population are likely underreported. We demonstrated equivalence between the patient-centered ALERT-B and medically-focused CTCAE surveys. In this LMIC setting, ALERT-B offers a path to GI toxicity data collection that improves efficiency and data volume collected, improving patient quality of life.
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500702
Artificial Intelligence–Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning With the Radiation Planning Assistant
PURPOSE: Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps that can contribute to treatment delays and interobserver variability. The Radiation Planning Assistant (RPA) is a Web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, artificial intelligence–driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries. MATERIALS AND METHODS: We developed deep learning–based auto-contouring models using nnU-Net and integrated them with knowledge-based planning models trained on curated data sets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. RESULTS: In all, 50 test patients (40 prostate, 10 cervical) were evaluated end-to-end. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. CONCLUSION: We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA's infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500702
Open AccessArtificial Intelligence–Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning With the Radiation Planning Assistant
PURPOSE: Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps that can contribute to treatment delays and interobserver variability. The Radiation Planning Assistant (RPA) is a Web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, artificial intelligence–driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries. MATERIALS AND METHODS: We developed deep learning–based auto-contouring models using nnU-Net and integrated them with knowledge-based planning models trained on curated data sets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. RESULTS: In all, 50 test patients (40 prostate, 10 cervical) were evaluated end-to-end. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. CONCLUSION: We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA's infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (6) , 939-950
Implementation of Quality Improvement Interventions in Medical Oncology: A Systematic Review
PURPOSE: As global cancer rates rise, the demand for effective, high-quality delivery of systemic anticancer therapy (SACT) is crucial. However, quality improvement (QI) research in medical oncology remains limited. This systematic review aims to identify and characterize QI interventions addressing quality deficits in medical oncology practice, focusing on intervention types, methodologies, and outcomes. METHODS: A systematic search of EMBASE and MEDLINE was conducted from January 2000 to November 2024, following PRISMA guidelines (PROSPERO: CRD42024579992). Studies were included if they evaluated a QI intervention in medical oncology using a baseline measurement and aiming to address a predefined quality deficit in patient-related outcomes. Data on study design, intervention types, quality deficits, and outcomes were extracted, and study quality was assessed using the QI Minimum Quality Criteria Set (QI-MQCS). RESULTS: Of the 11,655 studies identified, 28 met the inclusion criteria. Five key themes emerged: waiting times for SACT delivery at infusion visits, delays in commencement of initial SACT, optimal utilization of SACT, side effects of SACT, and safety. Most studies were conducted in the United States (n = 17), at a single center (n = 27) with only one national-level study. Funding was reported in three studies (two industry-sponsored, one philanthropic). All studies demonstrated a positive impact on at least one patient-related outcome measure. QI-MQCS scores ranged from 11 to 16 of 16. CONCLUSION: Although cancer treatment continues to evolve, QI strategies in medical oncology remain underexplored. While all identified interventions were beneficial, generalizability is limited by single-center settings and methodological constraints. Expansion of QI research beyond the United States, adoption of stronger study designs, and increased investment in QI training and infrastructure are needed. Multilevel support and sustainable funding are essential to scale up evidence-based QI efforts and improve oncology care globally.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (6) , 939-950
Implementation of Quality Improvement Interventions in Medical Oncology: A Systematic Review
PURPOSE: As global cancer rates rise, the demand for effective, high-quality delivery of systemic anticancer therapy (SACT) is crucial. However, quality improvement (QI) research in medical oncology remains limited. This systematic review aims to identify and characterize QI interventions addressing quality deficits in medical oncology practice, focusing on intervention types, methodologies, and outcomes. METHODS: A systematic search of EMBASE and MEDLINE was conducted from January 2000 to November 2024, following PRISMA guidelines (PROSPERO: CRD42024579992). Studies were included if they evaluated a QI intervention in medical oncology using a baseline measurement and aiming to address a predefined quality deficit in patient-related outcomes. Data on study design, intervention types, quality deficits, and outcomes were extracted, and study quality was assessed using the QI Minimum Quality Criteria Set (QI-MQCS). RESULTS: Of the 11,655 studies identified, 28 met the inclusion criteria. Five key themes emerged: waiting times for SACT delivery at infusion visits, delays in commencement of initial SACT, optimal utilization of SACT, side effects of SACT, and safety. Most studies were conducted in the United States (n = 17), at a single center (n = 27) with only one national-level study. Funding was reported in three studies (two industry-sponsored, one philanthropic). All studies demonstrated a positive impact on at least one patient-related outcome measure. QI-MQCS scores ranged from 11 to 16 of 16. CONCLUSION: Although cancer treatment continues to evolve, QI strategies in medical oncology remain underexplored. While all identified interventions were beneficial, generalizability is limited by single-center settings and methodological constraints. Expansion of QI research beyond the United States, adoption of stronger study designs, and increased investment in QI training and infrastructure are needed. Multilevel support and sustainable funding are essential to scale up evidence-based QI efforts and improve oncology care globally.
- Open Access
- 17 February 2026
- Published by Wiley in BJU International
- Vol. 137 (5) , 840-848
Characteristics and outcomes of men presenting with complications of metastatic prostate cancer
Objectives: To describe the incidence, characteristics and mortality of men who present with complications of metastatic prostate cancer, a previously under‐reported population. We investigate men who present with and without malignant ureteric obstruction (MUO) and skeletal‐related events (SREs), collectively termed ‘metastatic‐related events’ (MREs). Patients and Methods: We used the English Cancer Registry linked to hospital administrative data to identify men diagnosed with metastatic prostate cancer between January 2015 and December 2022. Poisson regression models estimated adjusted relative risks (aRRs) of presenting with MREs. The cumulative incidences of overall and prostate cancer‐specific death were estimated for each MRE subgroup (metastatic without MRE, MUO, SRE, and MUO and SRE in combination). Results: Of 48 171 men diagnosed with primary metastatic disease, 4272 (8.9%) presented with MREs. Of these men, 2453 (57.4%) had MUO, 1738 (40.7%) had a SRE, and 81 (1.9%) had both. Men aged ≥80 years had the highest risk (9.8% [1604/16452]) of presenting with MREs. Men aged 70–79 years (8.0% [1470/18397]) (aRR 0.82, 95% confidence interval [CI] 0.77–0.88) and men aged 60–69 years (8.9% [916/10297]) (aRR 0.91, 95%CI 0.84–0.98) had lower risks. Men from the most deprived neighbourhoods (9.3% [706/7609]) (aRR 1.27, 95% CI 1.15–1.40) had greater risks of presenting with MREs than those from the least deprived neighbourhoods (8.0% [868/10865]). The proportion of men presenting with MREs varied across geographical regions, ranging from 4.6% (288/6233) to 11.7% (461/3951). The 5‐year overall mortality for men presenting without MREs was 57.8% (95% CI 57.2–58.4%), compared to 77.1% (95% CI 74.9–79.2%) with MUO, 66.8% (95% CI 64.1–69.4%) with a SRE and 84.4% (95% CI 74.1–94.7%) with both. Conclusions: The risk of presenting with metastatic prostate cancer and MREs varies according to age, socioeconomic deprivation, and residential region. These men have poorer survival outcomes than men diagnosed without MREs at diagnosis.
- 17 February 2026
- Published by Wiley in BJU International
- Vol. 137 (5) , 840-848
Open AccessCharacteristics and outcomes of men presenting with complications of metastatic prostate cancer
Objectives: To describe the incidence, characteristics and mortality of men who present with complications of metastatic prostate cancer, a previously under‐reported population. We investigate men who present with and without malignant ureteric obstruction (MUO) and skeletal‐related events (SREs), collectively termed ‘metastatic‐related events’ (MREs). Patients and Methods: We used the English Cancer Registry linked to hospital administrative data to identify men diagnosed with metastatic prostate cancer between January 2015 and December 2022. Poisson regression models estimated adjusted relative risks (aRRs) of presenting with MREs. The cumulative incidences of overall and prostate cancer‐specific death were estimated for each MRE subgroup (metastatic without MRE, MUO, SRE, and MUO and SRE in combination). Results: Of 48 171 men diagnosed with primary metastatic disease, 4272 (8.9%) presented with MREs. Of these men, 2453 (57.4%) had MUO, 1738 (40.7%) had a SRE, and 81 (1.9%) had both. Men aged ≥80 years had the highest risk (9.8% [1604/16452]) of presenting with MREs. Men aged 70–79 years (8.0% [1470/18397]) (aRR 0.82, 95% confidence interval [CI] 0.77–0.88) and men aged 60–69 years (8.9% [916/10297]) (aRR 0.91, 95%CI 0.84–0.98) had lower risks. Men from the most deprived neighbourhoods (9.3% [706/7609]) (aRR 1.27, 95% CI 1.15–1.40) had greater risks of presenting with MREs than those from the least deprived neighbourhoods (8.0% [868/10865]). The proportion of men presenting with MREs varied across geographical regions, ranging from 4.6% (288/6233) to 11.7% (461/3951). The 5‐year overall mortality for men presenting without MREs was 57.8% (95% CI 57.2–58.4%), compared to 77.1% (95% CI 74.9–79.2%) with MUO, 66.8% (95% CI 64.1–69.4%) with a SRE and 84.4% (95% CI 74.1–94.7%) with both. Conclusions: The risk of presenting with metastatic prostate cancer and MREs varies according to age, socioeconomic deprivation, and residential region. These men have poorer survival outcomes than men diagnosed without MREs at diagnosis.
- Open Access
AI-Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning with the Radiation Planning Assistant (RPA)
Purpose Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps and clinical hand-offs that contribute to treatment delays and inter-observer variability. The Radiation Planning Assistant (RPA) is a web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, AI-driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries (LMICs). Methods We developed deep learning-based auto-contouring models using nnU-Net and integrated them with knowledge-based planning (KBP) models trained on curated datasets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. Results In total, 50 test patients (40 prostate, 10 cervical) were evaluated. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. Conclusion We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA’s infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability. By reducing reliance on specialist input, this work addresses key barriers to equitable radiotherapy access in resource-limited settings and responds to global calls from the IAEA and WHO to expand radiotherapy capacity. Funding National Institute of Health, National Science Foundation, Rising Tide Foundation, University of Texas MD Anderson Cancer Center
Open AccessAI-Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning with the Radiation Planning Assistant (RPA)
Purpose Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps and clinical hand-offs that contribute to treatment delays and inter-observer variability. The Radiation Planning Assistant (RPA) is a web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, AI-driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries (LMICs). Methods We developed deep learning-based auto-contouring models using nnU-Net and integrated them with knowledge-based planning (KBP) models trained on curated datasets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. Results In total, 50 test patients (40 prostate, 10 cervical) were evaluated. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. Conclusion We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA’s infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability. By reducing reliance on specialist input, this work addresses key barriers to equitable radiotherapy access in resource-limited settings and responds to global calls from the IAEA and WHO to expand radiotherapy capacity. Funding National Institute of Health, National Science Foundation, Rising Tide Foundation, University of Texas MD Anderson Cancer Center
- Open Access
- 2 July 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 226, 115594
The effect of centralising novel cell therapies for solid cancers – a health systems planning model for Europe
- 2 July 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 226, 115594
Open AccessThe effect of centralising novel cell therapies for solid cancers – a health systems planning model for Europe
- Open Access
- 26 May 2025
- Published by Wiley in International Journal of Cancer
- Vol. 157 (6) , 1043-1054
Characteristics of interventions aimed at reducing inequalities along the cancer continuum: A scoping review
Cancer inequalities are wide and enduring, within countries between socio‐demographic groups and between countries. These are generated and sustained throughout the key phases of the cancer pathway, from investigation, clinical assessment, decision and access to treatment, and follow‐up care. We aimed to describe the characteristics of implemented interventions, evaluated in published controlled experiments in the medical literature, specifically designed to target reductions in inequalities along the cancer pathway. We searched the Ovid Medline and Embase databases from January 2005 to April 2024 for controlled experiments reporting on interventions tackling inequalities. We extracted information on the publication, the aim and type of intervention, its setting, the characteristics of the sample and of the interventions, and summarised their results and limitations. We identified 56 articles reporting on 57 interventions. Of these, 51 (89.5%) focused on access to screening; 56 (98.2%) focused on colorectal, breast, and cervical cancers; 37 (64.9%) concentrated on ethnic inequalities and 48 (84.2%) were based in the USA. In addition, the majority of interventions sought to change individual knowledge, beliefs, and behaviour rather than issues at the system‐level. The importance of addressing how healthcare is delivered equitably to all individuals is widely recognised, and there is evidence that individual factors account for only a small part of cancer pathway inequalities. Yet, this scoping review reports a lack of diversity in the implementation of interventions addressing cancer inequalities, and a minority of them target health system issues.
- 26 May 2025
- Published by Wiley in International Journal of Cancer
- Vol. 157 (6) , 1043-1054
Open AccessCharacteristics of interventions aimed at reducing inequalities along the cancer continuum: A scoping review
Cancer inequalities are wide and enduring, within countries between socio‐demographic groups and between countries. These are generated and sustained throughout the key phases of the cancer pathway, from investigation, clinical assessment, decision and access to treatment, and follow‐up care. We aimed to describe the characteristics of implemented interventions, evaluated in published controlled experiments in the medical literature, specifically designed to target reductions in inequalities along the cancer pathway. We searched the Ovid Medline and Embase databases from January 2005 to April 2024 for controlled experiments reporting on interventions tackling inequalities. We extracted information on the publication, the aim and type of intervention, its setting, the characteristics of the sample and of the interventions, and summarised their results and limitations. We identified 56 articles reporting on 57 interventions. Of these, 51 (89.5%) focused on access to screening; 56 (98.2%) focused on colorectal, breast, and cervical cancers; 37 (64.9%) concentrated on ethnic inequalities and 48 (84.2%) were based in the USA. In addition, the majority of interventions sought to change individual knowledge, beliefs, and behaviour rather than issues at the system‐level. The importance of addressing how healthcare is delivered equitably to all individuals is widely recognised, and there is evidence that individual factors account for only a small part of cancer pathway inequalities. Yet, this scoping review reports a lack of diversity in the implementation of interventions addressing cancer inequalities, and a minority of them target health system issues.
- 2 April 2025
- Published by Elsevier in The Lancet Oncology
- Vol. 26 (4) , e225-e232
The National Cancer Audit Collaborating Centre (NATCAN): improving the quality of National Health Service cancer care in England and Wales
- 2 April 2025
- Published by Elsevier in The Lancet Oncology
- Vol. 26 (4) , e225-e232
The National Cancer Audit Collaborating Centre (NATCAN): improving the quality of National Health Service cancer care in England and Wales
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400615
Navigating Scientific Progress in Radiation Oncology: Comprehensive Analysis of Clinical Trials From the Past Two Decades Using the ClinicalTrials.gov Database
PURPOSE: Oncology has experienced substantial growth in clinical trial activity over the past two decades, but a comprehensive evaluation of radiation oncology research is lacking. This study analyzed trends in radiation therapy trials using data from ClinicalTrials.gov. MATERIALS AND METHODS: A comprehensive analysis was conducted on 4,253 radiation oncology trials registered in the database. Key outcomes examined included trends in trial activity over time, the geographic distribution of trials, and the phases of clinical trials conducted. RESULTS: Clinical trial activity in radiation oncology has increased significantly, with 4,253 trials registered by February 2024. Digestive, CNS, and head and neck cancers accounted for 49.7% of studies. Research on oligometastasis emerged in the past decade (2.2%), while hematology trials declined (9.7%). Phase II trials dominated (51.3%), with most originating in North America (58.2%). Europe (21.2%) and Asia (25.2%) have shown increasing contributions, reflecting a global shift. Only 6% of trials received industry funding, highlighting the financial challenges in the field. CONCLUSION: These findings underscore the dynamic nature of radiation oncology research and the need to address regional disparities, advance novel technologies and drug-radiotherapy combinations through phase I and III trials, and increase industry investment.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400615
Navigating Scientific Progress in Radiation Oncology: Comprehensive Analysis of Clinical Trials From the Past Two Decades Using the ClinicalTrials.gov Database
PURPOSE: Oncology has experienced substantial growth in clinical trial activity over the past two decades, but a comprehensive evaluation of radiation oncology research is lacking. This study analyzed trends in radiation therapy trials using data from ClinicalTrials.gov. MATERIALS AND METHODS: A comprehensive analysis was conducted on 4,253 radiation oncology trials registered in the database. Key outcomes examined included trends in trial activity over time, the geographic distribution of trials, and the phases of clinical trials conducted. RESULTS: Clinical trial activity in radiation oncology has increased significantly, with 4,253 trials registered by February 2024. Digestive, CNS, and head and neck cancers accounted for 49.7% of studies. Research on oligometastasis emerged in the past decade (2.2%), while hematology trials declined (9.7%). Phase II trials dominated (51.3%), with most originating in North America (58.2%). Europe (21.2%) and Asia (25.2%) have shown increasing contributions, reflecting a global shift. Only 6% of trials received industry funding, highlighting the financial challenges in the field. CONCLUSION: These findings underscore the dynamic nature of radiation oncology research and the need to address regional disparities, advance novel technologies and drug-radiotherapy combinations through phase I and III trials, and increase industry investment.